Pembrolizumab in patients with recurrent thymic carcinoma: Results of a phase II study.

被引：9
|
作者：
Giaccone, Giuseppe
Thompson, Jillian
McGuire, Colleen
Manning, Maria
Kallakury, Bhaskar
Chahine, Joeffrey J.
Subramaniam, Deepa Suresh
Liu, Stephen V.
Gibney, Geoffrey Thomas
Kim, Chul
McCutcheon, Justine N.
机构：
[1] Georgetown Univ, Washington, DC USA
[2] Georgetown Univ, Med Ctr, Washington, DC 20007 USA
[3] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA
[4] Georgetown Univ Hosp, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA
[5] NIH, NCI, Thorac & Gastrointestinal Oncol Branch, Ctr Canc Res, Bldg 10, Bethesda, MD 20892 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.8573
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8573
引用
收藏
页数：5
相关论文
共 50 条
  • [41] Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): Results of a phase II study.
    Trigo, J
    Hitt, R
    Koralewski, P
    Diaz-Rubio, E
    Rolland, F
    Knecht, R
    Amellal, N
    Bessa, EH
    Baselga, J
    Vermorken, JB
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 488S - 488S
  • [42] Concurrent cetuximab (CTX) and nivolumab (NIVO) in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Results of phase II study.
    Chung, Christine H.
    Bonomi, Marcelo Raul
    Steuer, Conor Ernst
    Schell, Michael J.
    Li, Jiannong
    Johnson, Matthew
    Masannat, Jude
    Hernandez-Prera, Juan C.
    McMullen, Caitlin
    Wadsworth, J.
    Patel, Krupal
    Kish, Julie Ann
    Muzaffar, Jameel
    Kirtane, Kedar
    Rocco, James William
    Saba, Nabil F.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [43] A PHASE II TRIAL OF PEMBROLIZUMAB AND LENVATINIB IN RECURRENT OR PERSISTENT CLEAR CELL CARCINOMA OF THE OVARY
    Lee, Elizabeth
    Tayob, Nabihah
    Rimel, Bj
    Hendrickson, Andrea Wahner
    Nixon, Andrew
    Matulonis, Ursula
    Liu, Joyce
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A238 - A238
  • [44] COMBINATION THERAPY WITH BEVACIZUMAB AND GEMOX FOR PATIENTS WITH RECURRENT OVARIAN CANCERS: A PHASE II STUDY.
    Takano, M.
    Ikeda, Y.
    Kouta, H.
    Sasaki, N.
    Goto, T.
    Kudoh, K.
    Kita, T.
    Kikuchi, R.
    Furuya, K.
    Kikuch, Y.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (09) : 381 - 382
  • [45] COMBINATION THERAPY WITH BEVACIZUMAB AND GEMOX FOR PATIENTS WITH RECURRENT OVARIAN CANCERS: A PHASE II STUDY.
    Takano, M.
    Ikeda, Y.
    Oda, K.
    Kouta, H.
    Kudoh, K.
    Kita, T.
    Naoki, S.
    Goto, T.
    Furuya, K.
    Kikuchi, Y.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (08)
  • [46] Randomized Phase II Study of Pembrolizumab after SBRT versus Pembrolizumab Alone in Patients with Advanced NSCLC, Preliminary Results
    Theelen, Willemijn
    Lalezari, Ferry
    Van Den Heuvel, Michel
    Baas, Paul
    Peulen, Heike
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1453 - S1453
  • [47] A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
    Mahmood, Umair
    Bang, Andrew
    Chen, Yu-Hui
    Mak, Raymond H.
    Lorch, Jochen H.
    Hanna, Glenn J.
    Nishino, Mizuki
    Manuszak, Claire
    Thrash, Emily M.
    Severgnini, Mariano
    Sanborn, Matthew
    Sridharan, Vishwajith
    Margalit, Danielle N.
    Tishler, Roy B.
    Busse, Paul M.
    Willers, Henning
    Mamon, Harvey J.
    Yoo, Hyung-Jin
    Pai, Sara, I
    Wirth, Lori J.
    Haddad, Robert, I
    Chau, Nicole G.
    Schoenfeld, Jonathan D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 109 (01): : 134 - 144
  • [48] Phase II trial of combination pembrolizumab, olaparib, and temozolomide for patients with recurrent glioma
    Schaff, Lauren
    Fortunato, John
    Grommes, Christian
    Gavrilovic, Igor T.
    Lin, Andrew
    Pentsova, Elena
    Miller, Alex
    Newton, Adam
    Gonzalez, Ashley
    Mellinghoff, Ingo K.
    Kaley, Thomas Joseph
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [49] Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study
    Katsuya, Yuki
    Horinouchi, Hidehito
    Seto, Takashi
    Umemura, Shigeki
    Hosomi, Yukio
    Satouchi, Miyako
    Nishio, Makoto
    Kozuki, Toshiyuki
    Hida, Toyoaki
    Sukigara, Tamie
    Nakamura, Kenichi
    Kuchiba, Aya
    Ohe, Yuichiro
    EUROPEAN JOURNAL OF CANCER, 2019, 113 : 78 - 86
  • [50] Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study
    Majd, Nazanin
    Waguespack, Steven G.
    Janku, Filip
    Fu, Siqing
    Penas-Prado, Marta
    Xu, Mingxuan
    Alshawa, Anas
    Kamiya-Matsuoka, Carlos
    Raza, Shaan M.
    McCutcheon, Ian E.
    Naing, Aung
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
12345